<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01386268</url>
  </required_header>
  <id_info>
    <org_study_id>14927</org_study_id>
    <secondary_id>KG0910KR</secondary_id>
    <nct_id>NCT01386268</nct_id>
  </id_info>
  <brief_title>Kogenate FS Regulatory Post-Marketing Surveillance</brief_title>
  <acronym>KG0910KR</acronym>
  <official_title>KOGENATEÂ® FS , Local Post Authorization Safety Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To obtain data on safety, efficacy, and tolerability of KOGENATE FS under real-life
      conditions in its registered indications.

      The observation period for each patient is up to 6 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety variables will be summarized using descriptive statistics based on adverse events collection</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Type of the treatment (prophylaxis, on demand, surgery)</measure>
    <time_frame>Initial visit and 6 month f/u or at the end of the observation visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total consumption of FVIII</measure>
    <time_frame>Initial visit and 6 month f/u or at the end of the observation visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily dosage/frequency of FVIII (if used for prophylaxis, on demand, surgery/peri-operatively)</measure>
    <time_frame>Initial visit, 6 month follow-up visit and 12 month follow-up visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General assessment of therapy by physician by grading from 1 to 4: 1) excellent; 2) good; 3) sufficient; 4) insufficient</measure>
    <time_frame>6 month f/u or at the end of observation visit</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">64</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Factor VIII (Kogenate FS, BAY14-2222)</intervention_name>
    <description>Patients with diagnosis of hemophilia A, treated with KOGENATE FS as their only source of FVIII, decision taken by the investigator to administer KOGENATE FS</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with hemophilia A in Korea
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with diagnosis of hemophilia A

          -  Treated with KOGENATE FS as their only source of FVIII, decision taken by the
             investigator to administer KOGENATE FS

          -  Signed the informed consent form to participate in this study.

          -  For pretreated patients with more than 100 exposure days an inhibitor assessment
             within three months prior to enrollment should be available

          -  For pretreated patients with less than 100 exposure days an inhibitor assessment at
             baseline should be available

          -  For patients with no available inhibitor status, it should be checked as per the
             recommendation of KFDA

          -  Patients are defined as included in the study if there is a documented prescription of
             KOGENATE FS by the physician.

        Exclusion Criteria:

          -  Patients with hypersensitivity to any ingredient of KOGENATE FS or to the protein of
             mouse or hamster will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Many locations</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here and search for websynopsis results</description>
  </link>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2011</study_first_submitted>
  <study_first_submitted_qc>June 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2011</study_first_posted>
  <last_update_submitted>August 20, 2014</last_update_submitted>
  <last_update_submitted_qc>August 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kogenate FS</keyword>
  <keyword>Hemophilia A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

